Corinne Foley
About Corinne Foley
Corinne Foley is a Senior Scientist at Arcus Biosciences, where she has worked since 2017. She previously served as a Postdoctoral Research Fellow at Memorial Sloan Kettering Cancer Center and holds a Ph.D. in Organic Chemistry from Columbia University.
Current Role at Arcus Biosciences
Corinne Foley serves as a Senior Scientist at Arcus Biosciences, a position she has held since 2017. In this role, she focuses on the discovery and development of innovative cancer therapies. Her work involves significant contributions to the research and characterization of small-molecule AXL kinase inhibitors, which are designed to be orally bioavailable and selective for cancer treatment. Based in the San Francisco Bay Area, she collaborates with a team of scientists to advance the company's therapeutic pipeline.
Previous Experience at Memorial Sloan Kettering Cancer Center
Prior to her current role, Corinne Foley worked as a Postdoctoral Research Fellow at Memorial Sloan Kettering Cancer Center from 2014 to 2017. During her three years in the Greater New York City Area, she conducted advanced research in the field of cancer biology. This experience provided her with a strong foundation in scientific research methodologies and contributed to her expertise in oncology.
Education and Academic Background
Corinne Foley completed her Bachelor of Arts (B.A.) in Chemistry at the University of Pennsylvania from 2005 to 2009. She then pursued her Doctor of Philosophy (Ph.D.) in Organic Chemistry at Columbia University in the City of New York, where she studied from 2009 to 2014. Her academic training has equipped her with a deep understanding of chemical principles and their applications in drug discovery.
Research Contributions and Presentations
Corinne Foley has presented her research at prominent scientific gatherings, including the American Chemical Society Spring Meeting in March 2023. Her research contributions include the development of potent and selective AXL receptor tyrosine kinase inhibitors, which are significant in the context of cancer therapy. Her work in this area reflects her commitment to advancing therapeutic options for patients.